gc012f
gracell biotechnologies
['car-t']
 fast car-t targeting bmca/cd-19 mm patients that are triple refractory (some penta-rfx) are produced in &lt;48h in shanghai and show &gt;90% orr! impressive!!! car-ts are getting better, faster, safer! #eha2022 
Internal Medicine, Haematology and Oncology resident. Stem Cell Therapy Unit - University Hospital Augsburg. Passionate about AML, SCT and cellular therapies.